** Shares of gene therapy firm MeiraGTx MGTX.O rise 7.3% to $14.90 premarket

** Co says it secured up to $400 mln from Oberland Capital to advance three late-stage experimental gene therapies

** Funding includes up to $375 mln in non-dilutive financing tied to future sales royalties and up to $25 mln in equity investment

** Co says it has already received $135 mln, including $125 mln for future royalties and $10 mln in equity

** Additional $150 mln available upon positive trial data and regulatory approvals expected in 2027-2028

** Oberland may provide another $100 mln for new products or business development and can buy an additional $15 mln in MeiraGTx shares, MGTX says

** As of last close, stock was up ~75% YTD